Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001641172-25-001810
Filing Date
2025-03-31
Accepted
2025-03-31 16:52:50
Documents
90
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-k.htm   iXBRL 10-K 3810473
2 ex-4_vi.htm EX-4.VI 76790
3 ex23-1.htm EX-23.1 3717
4 ex31-1.htm EX-31.1 18556
5 ex31-2.htm EX-31.2 18272
6 ex32-1.htm EX-32.1 7634
7 ex32-2.htm EX-32.2 7899
8 form10-k_001.jpg GRAPHIC 66712
  Complete submission text file 0001641172-25-001810.txt   14843583

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE cldi-20241231.xsd EX-101.SCH 97709
10 XBRL CALCULATION FILE cldi-20241231_cal.xml EX-101.CAL 104078
11 XBRL DEFINITION FILE cldi-20241231_def.xml EX-101.DEF 428334
12 XBRL LABEL FILE cldi-20241231_lab.xml EX-101.LAB 826217
13 XBRL PRESENTATION FILE cldi-20241231_pre.xml EX-101.PRE 613396
92 EXTRACTED XBRL INSTANCE DOCUMENT form10-k_htm.xml XML 2015324
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

EIN.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-40789 | Film No.: 25794389
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)